Modulators of calcium release-activated calcium channel
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
1. A compound of formula
or a tautomer, prodrug, N-oxide, pharmaceutically acceptable ester or pharmaceutically acceptable salt thereof, wherein
Ring Hy represents
optionally substituted with R′″;
R 1 and R 2 are the same or different and are independently selected from CH 3 , CH 2 F, CHF 2 , CF 3 , substituted or unsubstituted C (3-5) cycloalkyl, CH 2 —OR a , CH 2 —NR a R b , CN and COOH with the proviso that;
a) both R 1 and R 2 at the same time do not represent CF 3 ,
b) both R 1 and R 2 at the same time do not represent CH 3 ,
c) when R 1 is CF 3 then R 2 is not CH 3 and
d) when R 1 is CH 3 then R 2 is not CF 3 ;
Ring Ar represents:
L 1 and L 2 together represent —NH—C(═O)—;
A is absent;
R′ and R″ are the same or different and are independently selected from hydrogen, hydroxy, cyano, halogen, —OR a , —COOR a , —S(═O) q —R a , —NR a R b , —C(═X)—R a , substituted or unsubstituted C (1-6) alkyl group, substituted or unsubstituted C (1-6) alkenyl, substituted or unsubstituted C (1-6) alkynyl, and substituted or unsubstituted C (3-5) cycloalkyl, or R′ and R″ may be joined to form a substituted or unsubstituted saturated or unsaturated 3-6 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR a and S;
R′″ is selected from hydrogen, hydroxy, cyano, halogen, —OR a , —COOR a , —S(═O) q —R a , —NR a R b , —C(═X)—R a , substituted or unsubstituted C (1-6) alkyl group, substituted or unsubstituted C (1-6) alkenyl, substituted or unsubstituted C (1-6) alkynyl, and substituted or unsubstituted C (3-5) cycloalkyl
each occurrence of X is independently selected from O, S and —NR a ;
Cy is selected from monocyclic substituted or unsubstituted cycloalkyl group, and monocyclic substituted or unsubstituted aryl;
each occurrence of R a and R b are the same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, —OR c , —S(═O) q —R c , —NR c R d , —C(═Y)—R c , —CR c R d —C(═Y)—R c , —CR c R d —Y—CR c R d —, —C(═Y)—NR c R d —, —NRR d —C(═Y)—NR c R d —, —S(═O) q —NR c R d —, —NR c R d —S(═O) q —NR c R d —, —NR c R d —NR c R d —, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocylyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl, or when R a and R b are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR c and S;
each occurrence of R c and R d may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, or when two R c and/or R d substitutents are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NH and S;
each occurrence of Y is selected from O, S and —NR a ; and
each occurrence of q independently represents 0, 1 or 2.
2. A compound of claim 1 , wherein Hy is selected from
3. A compound of claim 1 , wherein Hy is
4. A compound of claim 1 , wherein Ar is selected from
5. A compound of claim 1 , wherein Cy is
6. A compound of claim 5 , wherein Cy is selected from
7. A compound of claim 1 , wherein the compound has the formula (IA)
or a tautomer, prodrug, N-oxide, pharmaceutically acceptable ester, or pharmaceutically acceptable salt thereof, wherein
R 1 and R 2 are the same or different and are independently selected from CH 3 , CH 2 F, CHF 2 , CF 3 , substituted or unsubstituted C (3-5) cycloalkyl, CH 2 —OR a , CH 2 —NR a R b , CN and COOH with the proviso that;
a) both R 1 and R 2 at the same time do not represent CF 3 ,
b) both R 1 and R 2 at the same time do not represent CH 3 ,
c) when R 1 is CF 3 then R 2 is not CH 3 and
d) when R 1 is CH 3 then R 2 is not CF 3 ;
U, V and W are the same or different and are independently selected from CR a ;
T is N;
L 1 and L 2 together represent —NH—C(═O)—;
A is absent;
each occurrence of R′ and R″ are the same or different and are independently selected from hydrogen, hydroxy, cyano, halogen, —OR a , —COOR a , —S(═O) q —R a , —NR a R b , —C(═X)—R a , substituted or unsubstituted C (1-6) alkyl group, substituted or unsubstituted C (1-6) alkenyl, substituted or unsubstituted C (1-6) alkynyl, and substituted or unsubstituted C (3-5) cycloalkyl, or R′ and R″ may be joined to form a substituted or unsubstituted saturated or unsaturated 3-6 membered ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR a and S;
R′″ is selected from hydrogen, hydroxy, cyano, halogen, —OR a , —COOR a , —S(═O) q —R a , —NR a R b , —C(═X)—R a , substituted or unsubstituted C (1-6) alkyl group, substituted or unsubstituted C (1-6) alkenyl, substituted or unsubstituted C (1-6) alkynyl, and substituted or unsubstituted C (3-5) cycloalkyl;
each occurrence of X is independently selected from O, S and —NR a ;
Cy is selected from monocyclic substituted or unsubstituted cycloalkyl group, and monocyclic substituted or unsubstituted aryl;
each occurrence of R a and R b are the same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, —OR c , —S(═O) q —R c , —NR c R d , —C(═Y)—R c , —CR c R d —C(═Y)—R c , —CR c R d —Y—CR c R d —, —C(═Y)—NR c R d —, —NRR d —C(═Y)—NR c R d —, —S(═O) q —NR c R d —, —NR c R d —S(═O) q —NR c R d —, —NR c R d —NR c R d —, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocylyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl, or when R a and R b substitutent are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR c and S;
each occurrence of R c and R d may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, or when two R c and/or R d substitutents are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NH and S;
each occurrence of Y is selected from O, S and —NR a ; and
each occurrence of q independently represents 0, 1 or 2.
8. A compound of claim 7 , wherein both R 1 and R 2 represent cyclopropyl.
9. A compound of claim 7 , wherein one of R 1 and R 2 is CF 3 and the other is independently cyclopropyl, CH 2 F or CHF 2 .
10. A compound of claim 7 , wherein Cy is selected from
11. A compound of claim 1 , wherein the compound has the formula (IA-III)
or a tautomer, prodrug, N-oxide, pharmaceutically acceptable ester, or pharmaceutically acceptable salt thereof, wherein
R 1 and R 2 are the same or different and are independently selected from CH 2 F, CHF 2 , CF 3 , cyclopropyl with the proviso that both R 1 and R 2 at the same time do not represent CF 3 ;
T is N;
each of U, V and W is, independently CR a ;
L 1 and L 2 together represent —NH—C(═O)—;
A is absent;
each occurrence of R′ and R″ are the same or different and are independently selected from hydrogen or substituted or unsubstituted C (1-6) alkyl group or R′ and R″ may be joined to form a substituted or unsubstituted saturated or unsaturated 3-6 membered ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR a and S;
R′″ is selected from hydrogen or halogen;
each occurrence of X is independently selected from O, S and —NR a ;
Cy is substituted or unsubstituted aryl;
each occurrence of R a and R b are the same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, —OR c , —S(═O) q —R c , —NR c R d , —C(═Y)—R c , —CR c R d —C(═Y)—R c , —CR c R d —Y—CR c R d —, —C(═Y)—NR c R d —, —NRR d —C(═Y)—NR c R d —, —S(═O) q —NR c R d —, —NR c R d —S(═O) q —NR c R d —, —NR c R d —NR c R d —, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocylyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl, or when R a and R b substitutent are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR c and S;
each occurrence of R c and R d may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, or when two R c and/or R d substitutents are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NH and S;
each occurrence of Y is selected from O, S and —NR a ; and
each occurrence of q independently represents 0, 1 or 2.
12. A compound of claim 11 , wherein one of R 1 and R 2 is CF 3 and the other is cyclopropyl.
13. A compound of claim 11 , wherein one of R 1 and R 2 is CF 3 and the other is CH 2 F, CHF 2 .
14. A compound of claim 11 , wherein both R 1 and R 2 represent cyclopropyl.
15. A compound of claim 11 , wherein Cy is selected from
16. A compound selected from:
N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-fluorobenzamide
N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2,3-difluorobenzamide
N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2,6-difluorobenzamide
N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2-methylbenzamide
2-chloro-N-6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl 1 benzamide
N-(6-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-fluorobenzamide
N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2,3-difluorobenzamide
N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2,6-difluorobenzamide
or a tautomer, prodrug, N-oxide, pharmaceutically acceptable ester, or pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
18. N-(6-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-methylbenzamide or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition comprising a compound of claim 18 and a pharmaceutically acceptable carrier.
20. N-(6-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-methylbenzamide.
21. A pharmaceutical composition comprising a compound of claim 20 and a pharmaceutically acceptable carrier.
22. A method of treating asthma comprising the step of administering to a subject in need thereof an effective amount of a compound of claim 1 .
23. A method of treating rheumatoid arthritis comprising the step of administering to a subject in need thereof an effective amount of a compound of claim 1 .